University of Peloponesse
Μοντέλο υποστήριξης αποφάσεων για τη χάραξη φαρμακευτικής πολιτικής και αξιολόγηση εφαρμοσμένων εργαλείων
Abstract
dc:descriptionThis study introduces an innovative mathematical framework designed to quantify the societal cost associated with delays in the reimbursement and distribution of novel medicines. By integrating key public health and economic indicators—namely Years of Life Lost (YLL), Years of Potential Productive Life Lost (YPPLL), and Cost of Productivity Loss (CPL)—the proposed model provides a comprehensive assessment of the health, social, and economic consequences of delayed access to innovative therapies. The findings underscore the critical importance of timely pharmaceutical policy-making, particularly for medicines with high and well-documented clinical value. Delays in access not only reduce the therapeutic benefits available to patients but also amplify broader societal costs through increased premature mortality, diminished workforce participation, and heightened economic burden. The framework highlights that even relatively short delays may lead to disproportionately large losses in population health and productivity, emphasizing the need for differentiated policy approaches based on the clinical value of therapies. By adopting a broader societal perspective, the model supports a more balanced evaluation of pharmaceutical policy decisions, facilitating the trade-off between rapid patient access to innovation and the sustainability of healthcare expenditure. Furthermore, the framework functions as a decision-support tool for policymakers, enabling ex ante and ex post assessment of the societal and economic impact of reimbursement delays using data-driven methods. The study also highlights the pivotal role of data quality, completeness, and governance in ensuring reliable estimations of health and economic outcomes. Incomplete, inconsistent, or non-representative data may lead to biased assessments, suboptimal policy decisions, and inequities in access to healthcare. Overall, the proposed framework contributes to the advancement of value-based pharmaceutical policy by integratingreal-world data and mathematical modeling to maximize the societal benefits of medical innovation while safeguarding the long-term viability of healthcare systems.
Degree
thesis:*- Grantor dc:publisher
- University of Peloponesse
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theiakou, Foteini
- Θειακού, Φωτεινή
Subjects
dc:subject × 22- Φαρμακευτική πολιτική
- Καινοτόμα φάρμακα
- Καθυστέρηση πρόσβασης
- Μαθηματικά μοντέλα Υποστήριξη λήψης αποφάσεων
- Έτη ζωής που χάνονται (YLL)
- Κόστος παραγωγικότητας
- Πραγματικά δεδομένα
- Pharmaceutical policy
- Innovative medicines
- Social loss
- Reimbursement delays
- Mathematical model
- Data quality
- Delayed access
- Years of life lost
- Productivity loss
- Οικονομικά και Επιχειρήσεις
- Κοινωνικές Επιστήμες
- Επιστήμη λήψης αποφάσεων
- Economics and Business
- Social Sciences
- Decision Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/10442/hedi/61164